Skip to main content

Table 7 Results of the univariate regressiona (N = 193)

From: Benefit assessment in Germany: implications for price discounts

Predictor (X) n Beta SE Coeff (β) p-value R2
Additional benefit 100 −0.041 0.019 −0.156 0.030* 0.024
 Major 1 −0.084 0.132 −0.046 0.527 0.002
 Considerable 29 −0.015 0.027 −0.042 0.564 0.002
 Minor 48 −0.014 0.022 −0.045 0.532 0.002
 Non-quantifiable 22 −0.052 0.030 −0.127 0.078 0.016
 No additional benefit 92 0.044 0.019 0.167 0.020* 0.028
 Less benefit (additional harm potential) 1 −0.130 0.132 −0.071 0.324 0.005
Orphan status 29 −0.043 0.026 −0.117 0.104 0.014
Indication per category
 Certain infectious and parasitic diseases 51 0.001 0.022 0.002 0.975 0.000
 Diseases of the blood and blood-forming organs 2 0.026 0.094 0.020 0.784 0.000
 Diseases of the circulatory system 14 0.035 0.036 0.070 0.332 0.005
 Diseases of the digestive system 6 0.056 0.054 0.075 0.303 0.006
 Diseases of the eye and adnexa 7 −0.026 0.051 −0.037 0.609 0.001
 Diseases of the genitourinary system 2 −0.022 0.094 −0.017 0.816 0.000
 Diseases of the musculoskeletal system and connective tissue 1 0.176 0.131 0.096 0.183 0.008
 Diseases of the nervous system 9 0.167 0.043 0.268 0.000** 0.072
 Diseases of the respiratory system 9 −0.095 0.044 −0.152 0.034* 0.023
 Diseases of the skin and subcutaneous tissue 1 0.209 0.131 0.114 0.113 0.013
 Endocrine, nutritional and metabolic diseases 24 −0.024 0.029 −0.060 0.403 0.004
 Mental and behavioral disorders 2 0.038 0.094 0.029 0.689 0.001
 Neoplasms 57 −0.028 0.021 −0.097 0.181 0.009
 Other 8 −0.013 0.048 −0.020 0.787 0.000
Number of ACT >1 83 0.016 0.019 0.059 0.418 0.003
Incorporated HRQoL-data 49 −0.036 0.022 −0.119 0.100 0.014
  1. Abbreviations: HRQoL health-related quality of life, Beta standardized coefficient, SE standard error, Coeff coefficient, R 2 coefficient of determination
  2. ** Significant at the 0.01 level
  3. * Significant at the 0.05 level
  4. a Dependent Variable (Y): price change (discount)